CYGNUSBIO

Vendor Biography

Cygnus Biosciences (Beijing) Co., Ltd. is a national high-tech biotechnology company specializing in the research, development, manufacturing, and commercialization of advanced gene sequencing technologies. The company provides comprehensive genomic solutions, including sequencing instruments, reagents, consumables, and genetic testing services for global life science applications. Serving industries such as biomedical research, clinical diagnostics, pharmaceutical development, agriculture and breeding, disease control, forensic science, and evolutionary biology, Cygnus Biosciences is committed to delivering faster, more accurate, and cost-efficient DNA sequencing technologies to accelerate innovation and precision medicine worldwide. Core Technologies & Sequencing Innovation Cygnus Biosciences is a leader in next-generation sequencing (NGS) systems, with strong in-house R&D and independent intellectual property. Its core proprietary technologies include: Fluorogenic sequencing chemistry Error-correction code (ECC) sequencing LumoSeq sequencing platform AttoSeal technology With nearly 200 domestic and international patents, Cygnus covers the full sequencing ecosystem, including instruments, reagents, chips, and bioinformatics algorithms. The company’s flagship high-throughput sequencing platforms include: GS100 Sequencing System GP1000 Sequencing System GP1000X Sequencing System These systems are designed for high accuracy, scalability, and efficiency across research and clinical applications. Leadership Team & Scientific Expertise Cygnus Biosciences is founded and led by globally recognized scientists in genomics and biotechnology: Dr. Zitian Chen (Cofounder & CEO) Inventor of ECC sequencing technology and contributor to China’s National 863 Program for next-generation sequencing. Author of multiple scientific publications and holder of 50+ patents. PhD and postdoctoral training at Peking University. Academician Sunney X. Xie (Cofounder) Member of the U.S. National Academy of Sciences and National Academy of Medicine, Fellow of the American Academy of Arts and Sciences, and Academician of the Chinese Academy of Sciences. Former Harvard professor and pioneer in single-molecule biophysics. Prof. Yanyi Huang (Cofounder & Scientific Advisory Board Member) Professor at Peking University and key researcher at leading national innovation centers, including BIOPIC and the Beijing Advanced Innovation Center for Genomics. Expert in molecular engineering and life sciences. This leadership team provides strong scientific credibility and drives continuous innovation in sequencing technologies. Company History & Milestones Cygnus Biosciences has achieved rapid growth and technological breakthroughs since its founding: 2025 – Launch of P-series sequencing systems 2024 – Established Shenzhen Cygnus Medical Testing Laboratory 2023 – Achieved TÜV Rheinland ISO 13485 certification for medical device quality management 2022 – GS100 RUO launched; recognized as a National High-Tech Enterprise and Innovation China Emerging Enterprise 2021 – Completed GS100 type testing; recognized as a Beijing “Specialized and New” SME 2020 – Core patents licensed in the United States; established Guangzhou subsidiary 2019 – Recognized as Zhongguancun Frontier Technology Enterprise and Beijing Intellectual Property Pilot Unit 2011–2018 – Established Deneb Technology (Beijing); ECC sequencing technology published in Nature Biotechnology; company foundation established These milestones reflect Cygnus Biosciences’ strong trajectory in innovation, commercialization, and global expansion.